Research Topics
Species | D T TeacheySummaryAffiliation: The Children's Hospital of Philadelphia Country: USA Publications
| Collaborators
|
Detail Information
Publications
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALLDavid T Teachey
Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
Blood 107:1149-55. 2006..We conclude that MTIs can inhibit the growth of adult human ALL and deserve close examination as therapeutic agents against a disease that is often not curable with current therapy...- Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)David T Teachey
Children s Hospital of Philadelphia, University of Pennsylvania, 19104, USA
Br J Haematol 148:205-16. 2010..This review describes the clinical and laboratory manifestations found in ALPS patients, as well as the molecular basis for the disease and new advances in treatment... 
Pulmonary infection with microsporidia after allogeneic bone marrow transplantationD T Teachey
Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
Bone Marrow Transplant 33:299-302. 2004..Although rare, microsporidial infection should be considered in the differential diagnosis of unexplained pulmonary infection in bone marrow transplant patients...
Treatment with sirolimus ameliorates tacrolimus-induced autoimmune cytopenias after solid organ transplantDavid T Teachey
Division of Hematology, Children s Hospital of Philadelphia, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Pediatr Blood Cancer 53:1114-6. 2009..Altering the immunosuppressive regimen to modify T-cell dysregulation may be beneficial for patients who develop post-transplant autoimmune disease and allow continued preservation of allograft...- Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignanciesDavid T Teachey
Division of Paediatric Hematology, Children s Hospital of Philadelphia, 3615 Civic Centre Boulevard, Philadelphia, PA 19104, USA
Br J Haematol 145:569-80. 2009..This review describes the rationale for using mTOR inhibitors in a variety of haematological diseases with a focus on their use in leukaemia... - Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndromeDavid T Teachey
Pediatric Hematology and Oncology, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia PA 19104, USA
Br J Haematol 145:101-6. 2009..Based on these significant responses, we recommend that sirolimus be considered as second-line therapy for patients with steroid-refractory disease... - mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemiaDavid T Teachey
Division of Oncology, Department of Pediatrics, Children s Hospital of Philadelphia, PA 19104, USA
Blood 112:2020-3. 2008..We found methotrexate and MTIs are an effective and potentially synergistic combination in ALL... - Saddle pulmonary embolism as a complication of vasectomyDavid T Teachey
Department of Pediatric Hematology, Children s Hospital of Philadelphia, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USA
Urology 71:351.e5-6. 2008..This is the first report of a near fatal venous thromboembolic event resulting from vasectomy... - Targeting Notch signaling in autoimmune and lymphoproliferative diseaseDavid T Teachey
Department of Pediatrics, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine 19104, USA
Blood 111:705-14. 2008..Inhibiting the Notch signaling pathway may thus present an effective, novel, and well-tolerated treatment for autoimmune and lymphoproliferative diseases... - Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)David T Teachey
Divisions of Oncology and Hematology, Children s Hospital of Philadelphia, ARC 902, 3615 Civic Center Boulevard, Philadelphia, PA 19104, USA
Blood 108:1965-71. 2006..We conclude that rapamycin is an effective treatment for murine ALPS and should be explored as treatment for affected humans... - Daclizumab for children with corticosteroid refractory graft-versus-host diseaseD T Teachey
Division of Oncology in the Department of Pediatrics, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Bone Marrow Transplant 37:95-9. 2006..Daclizumab is a relatively safe and effective medication for corticosteroid refractory GVHD in children and larger studies are needed to evaluate its role in treatment... - Development of cold agglutinin autoimmune hemolytic anemia during treatment for pediatric acute lymphoblastic leukemiaDavid T Teachey
Division of Hematology, Department of Pediatrics, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
J Pediatr Hematol Oncol 27:397-9. 2005..The authors describe a child with B-cell precursor ALL who developed cold agglutinin AIHA during maintenance treatment while in remission after infection with influenza B... - Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative diseaseValerie I Brown
Division of Oncology, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, ARC 902, 3615 Civic Center Boulevard, Philadelphia, PA, 19104, USA
Immunol Res 42:84-105. 2008.... - Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS)David T Teachey
Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, ARC 902, 3615 Civic Center Blvd, Philadelphia, PA 19104, USA
Blood 105:2443-8. 2005..Our data further suggest that a number of patients with ES may have ALPS, a novel finding with important therapeutic implications... - Cell division rates of primary human precursor B cells in culture reflect in vivo ratesJonathan Cooperman
Pathology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
Stem Cells 22:1111-20. 2004..These findings indicate that the stroma-based cultures faithfully replicate in vivo cell division rates and can be used to elucidate the pathways that regulate cell division of primary human precursor B cells... - Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosisNaomi J Balamuth
Department of Pediatrics, Division of Oncology, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
J Pediatr Hematol Oncol 29:569-73. 2007..This patient demonstrated a rapid clinical response and an 18-fold reduction in EBV viral load within 24 hours of receiving rituximab. He remains free of disease 8 months after completing treatment... - In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotidesHisaki Fujii
Department of Pediatrics, Division of Hematology Oncology Bone Marrow Transplantation, University of British Columbia and British Columbia s Children s Hospital, Vancouver, Canada
Blood 109:2008-13. 2007..These results suggest that CpG ODNs have potential as therapeutic agents for the treatment of ALL...